Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Accelerate Diagnostics's
Operating Income
for the
three
months ended in Dec. 2024 was MXN-165.4 Mil. Accelerate Diagnostics's Interest Expense for the
three
months ended in Dec. 2024 was MXN-93.5 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Accelerate Diagnostics's Interest Coverage or its related term are showing as below:
MEX:AXDX's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.6 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Accelerate Diagnostics Interest Coverage Related Terms
Accelerate Diagnostics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:AXDX vs MSIU, BIOLQ, AFIB: Interest Coverage Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Accelerate Diagnostics did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Accelerate Diagnostics (MEX:AXDX) has a Interest Coverage of 0 (At Loss) as of Dec. 2024. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Interest Coverage too high?
Accelerate Diagnostics' current Interest Coverage is 0 (At Loss). Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Interest Coverage compare to MSIU and BIOLQ?
Accelerate Diagnostics' Interest Coverage of 0 (At Loss) can be compared against companies in the Medical Devices & Instruments industry. The industry median Interest Coverage is 16.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.60, based on 461 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accelerate Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accelerate Diagnostics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Interest Coverage is 0 (At Loss) as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
